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Abstract
Introduction: The expression of smooth muscle actin (SMA) and s100p has been identified on an
aggressive retro-orbital diffuse large B cell lymphoma (DLBCL) [1].
Aim: To assess the prognostic significance of immunohistochemical (IHC) expression of SMA and
s100p on DLBCL.
Materials and methods: Twenty nine cases diagnosed as DLBCL were first classified into
germinal centre (GC) B cell like and non GC origin either activated B cells (ABC) or type 3 based
on their immunoreactivity for CD10, bcl-6 and Mum-1. Bcl-2 and MIB-1 as adverse prognostic
factors were assessed. SMA and s100p were evaluated and correlated with patients'
clinicopathological characteristics.
Results: Eleven cases (37.93%) positive for CD10 and/or bcl-6 were classified as GC B cell like
subtype, 7 cases positive only for Mum-1 as ABC subtype (24.14%), and 11 cases double positive
or negative for bcl-6 and Mum-1 were considered as type 3 (37.93%). Nuclear and cytoplasmic SMA
and s100p were expressed in 58.62% and 51.72% of cases respectively and were strongly associated
with the non GC like phenotype (p < 0.001 for SMA and p < 0.01 for s100p). SMA and s100p were
strongly related to each other (p < 0.001). SMA was closely associated with bcl-2 and MIB-1 (p <
0.01 and p < 0.025 respectively), while s100p was only associated with bcl-2 (p < 0.05).
Conclusion:  SMA and s100p are expressed on non GC DLBCL and appear to be adverse
prognostic factors. Future large studies evaluating their significance will be valuable to assess the
different subgroups in clinical context. Lastly, this expression may lead to misdiagnosis of non
hematopoeitic neoplasm if lymphoid markers are not included in the IHC panel.
Background
The identification of a DLBCL positive for both SMA and
s100p was accidentally discovered during the diagnosis of
a retro-orbital mass of 3 months duration in a 37 years old
female [1]. Clinical and radiological differential diagnosis
was rhabdomyosarcoma, melanoma and lymphoma. An
initial panel included s100p, HMB45, SMA and LCA. Sur-
prisingly, s100p, SMA and LCA were positive on the neo-
plastic cells. Further immunostaining demonstrated
positivity of the neoplastic cells for CD20 and CD79a clas-
sifying the lesion as DLBCL, centroblastic polymorph var-
iant on histopathological basis. In addition, bcl-2 was
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positive while CD10, bcl-6 and CD138 were negative
indicating that this DLBCL neither of GC nor of ABC phe-
notype, was type 3 according to recent data of gene profil-
ing [2,3]. Patient died shortly after the diagnosis.
DLBCL as defined by the WHO classification [4] is an
umbrella term comprising heterogeneous biological enti-
ties at the molecular and clinical levels that cannot be dis-
tinguished by morphologic or immunophenotypic
analysis [5,6]. However, gene expression profiling divided
DLBCL into important subgroups with regard to progno-
sis as GC B cell like, ABC like and type 3 where the GC B
cell like group shows significantly better survival com-
pared to the other two groups [2,3]. Recently, bcl-6, CD10
and Mum-1 have been shown to be differently expressed
in the three phenotypes; both CD10 and bcl-6 are consid-
ered as GC markers, Mum-1 is expressed in the ABC group
while type 3 represents a grey zone negative for CD10
[2,3,7]. Other markers of prognostic significance include
bcl-2 [8-10] and MIB-1 [11], both are adverse prognostic
factors.
In the present work, we evaluated the expression of SMA
and s100p on DLBCL, and correlated this expression with
the site of presentation either nodal or extranodal, histo-
logic variants, GC or non GC phenotype and other
patient's clinicopathological characteristics. The clinical
outcome was assessed whenever possible.
Materials and methods
Patients and materials
Twenty nine cases diagnosed as de novo DLBCL either
nodal or extranodal, were retrieved from the Immunohis-
tochemistry Laboratory of Nasser Institute. Patients with
immunodeficiency-associated or post transplant tumors
were excluded. They were classified according to the WHO
classification [4] into centroblastic when more than 90%
of the cells were centroblasts, centroblastic polymorph
when the proportion of immunoblasts ranged from 10%
to 90%, and immunoblastic when more than 90% of
tumor cells were immunoblasts. The presence of Reed-
Sternberg like cells or cells with anaplastic features, plas-
macytoid, spindle and clear cells with abundant cyto-
plasm were reported for each case whenever identified.
Patients' characteristics, initial presentation, clinical stage
and clinical outcome if possible, were retrieved from the
pathological files.
Immunohistochemistry
IHC was effectuated on 5 µm thick paraffin embedded tis-
sue sections. The antibodies in the study, their sources,
clones, heat induced epitope antigen retrieval (HIER)
buffer and dilutions are illustrated in table 1. HIER was
done by heating the slides in microwave (800 watts) for
15 minutes (3 cycles × 5 minutes).
In brief, slides were hydrated in descending grades of alco-
hol followed by distilled water. Endogenous peroxidase
activity was quenched by 0.3% hydrogen peroxide for 5
minutes followed by rinsing in distilled water and three
times wash in phosphate buffer saline (PBS) pH 7.4. The
antibodies were incubated for 30 minutes and then the
slides were rinsed in successive bathes of PBS. The revela-
tion was done by the LSAB-2 detection kit (DakoCytoma-
tion) according to the manufacturer's instructions.
Finally, diaminobenzidine tetrachloride (DAB) was
applied for 5 minutes. Slides were counterstained in Har-
ris haematoxylin (Hx), dehydrated, cleared in xyelene and
coverslipped. Reactive nodes and internal control were
used as positive control for all antibodies. Slides with
omitted antibodies were used as negative control.
Interpretation of IHC
IHC results were evaluated in semi-quantitative manner
summarized in table 2. The intensity of staining was
assessed, but was not used to determine positivity because
paraffin blocks were obtained from different institutions
with variability in tissue fixation, processing and storage
Table 1: Antibodies used in the study
Antibodies Source Clone/Antibody HIER Dilution Incubation Staining interpretation
S100p DakoCytomation Rabbit polyclonal 1 1: 400 RT Nuclear -/+cytoplasmic
SMA DakoCytomation 1A4/monoclonal 2 1:50 RT Nuclear -/+cytoplasmic
CD20 DakoCytomation L26/monoclonal 2 1:200 RT Membranous
CD79a DakoCytomation JCB117/monoclonal 2 1:50 RT Membranous
CD10 Novocastra NCL-CD10-270/monoclonal 1 1:20 RT Membranous
Bcl-6 DakoCytomation BG-B6p/monoclonal 1 1:20 RT Nuclear
Mum-1 Santa Cruz goat polyclonal 2 1:50 37°C Nuclear, nucleolar
Bcl-2 DakoCytomation 124/monoclonal 2 1:50 RT Membranous
Ki-67 DakoCytomation MIB-1/monoclonal 1 1:75 RT Nuclear, nucleolar
1-Tris-EDTA pH9.0
2-Citrate buffer pH6.0
RT: room temperatureDiagnostic Pathology 2007, 2:9 http://www.diagnosticpathology.org/content/2/1/9
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conditions, factors that appeared to affect the intensity of
staining. The staining interpretation is summarized in
table 1.
Cases were subdivided into GC like B cells, ABC or type 3,
based on the positivity for CD10, bcl-6 and Mum-1. A case
was considered of GC like B cell origin if Mum-1 [12] was
negative and CD10 alone or both CD10 and bcl-6 were
positive [13,14]. ABC was considered when cells were
only positive for Mum-1 and type 3 when a case was neg-
ative for CD10 but double positive or negative for both
bcl-6 and Mum-1.
Statistical analysis
Chi-square test was used to test the association between
SMA and s100p IHC expression on one hand and the sub-
types, GC versus ABC versus type 3, and other categorical
variables on the other hand. On a latter step, both ABC
and type 3 was grouped together as non GC phenotype
since type 3 group has similar outcome as ABC group [3].
A cut-off point of 50% was used for MIB-1. The test was
considered positive when p value was equal to or less than
0.05.
Results
Sixteen patients were males and thirteen females. The age
ranged from 9–74 years with an average 45.20 years.
Eleven cases (37.93%) were negative for Mum-1, but pos-
itive for CD10 and/or bcl-6 and were classified as GC B
like cells. Seven cases (24.14 %) were CD10-bcl-6-Mum-
1+, favouring an ABC subtype. Eleven cases (37.93%)
were CD10-bcl-6+Mum-1+ (8/11) or CD10-bcl-6- Mum-
1- (3/11) and were considered type 3 (table 3). Case 13
and 27 died shortly after the diagnosis from disseminated
disease while the other cases are new ones actually receiv-
ing their treatment.
SMA and s100p were expressed in 58.62% and 51.72% of
cases respectively and were strongly associated with ABC
and type 3 (p < 0.01 for SMA and p < 0.025 for s100p).
Figures 1 through 10 illustrate a case of DLBCL, ABC sub-
type. However, when grouped into GC and non GC sub-
types, the association become more strong (p < 0.001 for
SMA p < 0.01 for s100p). Noteworthy, both SMA and
s100p were strongly related to each other (p < 0.001). In
addition, bcl-2 and MIB-1 were significantly expressed in
the non GC phenotype whether separated as ABC and
type 3 or grouped as non GC group (p < 0.001 for bcl-2
and p < 0.01 for MIB-1) (table 4). SMA was closely associ-
ated with bcl-2 and MIB-1 (p < 0.01 and p < 0.025 respec-
tively), while s100p was only associated with bcl-2 (p <
0.05). There was no relationship between the IHC expres-
sion of SMA and s100p and age, sex, clinical stage, site of
presentation, histological variants and predominant cell
type.
Discussion
SMA detects actin in smooth muscle, while s100 p is
present in glial cells, schwann cells, satellite cells, fat cells,
skeletal and heart muscle cells, melanocytes, chondro-
cytes, myoepithelial cells, some glandular epithelia and
follicular dendritic cells. In the English literature, few
reports identified SMA on B lymphocytes and B cell lym-
phoma (BCL), while s100p was observed on T cells and T
cell lymphoma (TCL). However, both markers have never
been reported together on BCL. Actin was thought to be
present on the surface of B and to a lesser extent on T cells;
an initial report with immunofluorescence misinterpreted
as a misleading result reflecting the presence of antibodies
cross reacting with immunoglobulin [15]. Further studies
identified actin as a major protein of human lymphocytes
[16-19].
Although this pilot study involved a limited number of
cases, it is the first report to our knowledge evaluating the
immunoreactivity of both SMA and s100p on DLBCL and
associating this expression with the GC B like and non GC
phenotype either ABC or type 3. We identified SMA and
s100p on non GC DLBCL phenotype pointing out to the
adverse effect of both markers, as recent data showed that
the non GC phenotype is a poor risk group [2,3]. Moreo-
ver, both markers were associated with bcl-2 expression, a
known adverse prognostic factor in DLBCL [8-10]. How-
ever, only SMA had a strong relationship with high prolif-
eration fraction as assessed by MIB-1 immunostaining.
This point is concordant with earlier research showing
that human B cell activation by receptor-mediated stim-
uli, results in actin polymerization changes in the
cytoskeleton, messages transduction and proliferation in
B lymphocytes [20]. Moreover, it has been proposed that
gelsolin, an actin-regulatory protein that modulates actin
assembly and disassembly promote cell growth through
inhibiting the apoptotic cell death program by a mecha-
nism independent from the bcl-2 family [21]. Does this
mechanism operate also on lymphoma cells? An interest-
ing point that needs to be answered. Furthermore, the
nuclear expression of actin in the present work, adds more
evidence on the aggressive nature of SMA+DLBCL as this
expression has an important role in nucleosome remodel-
Table 2: Guideline for interpretation of IHC scoring
Scoring % of positive cells
0 absence of staining up to 5%
+6 – 2 5 %
++ 26–50%
+++ 51–75%
++++ >75%Diagnostic Pathology 2007, 2:9 http://www.diagnosticpathology.org/content/2/1/9
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ling structure, transcription, and cell growth [22]. Other
studies implicated that nuclear actin interacts with RNA
polymerase II and may have function on the RNA
polymerase II-mediated transcription [23,24]. The clinical
impact of such immunoreactivity was evaluated in two
patients, classified as non GC phenotype (cases 13 and
27), strongly expressing SMA, s100p, bcl-2 and a high pro-
liferation fraction. Unfortunately, those patients died
shortly after diagnosis.
The expression of SMA on DLBCL has been published in
two reports. A 64-year-old male patient presented with
disseminated large non-cleaved BCL that exhibited sarco-
matoid and myxoid patterns and was strongly positive for
SMA. However, despite vigorous chemotherapy, the
patient died 3 months later [25]. The second report docu-
mented that four out of five extranodal DLBCL presenting
with prominent spindle cell morphology were actin posi-
tive [26]. However, we failed to found an association
between SMA immunoreactivity and histologic variants
and cellular morphology as sarcomatoid, anaplastic, clear
cell or spindle cells. In non haematological malignancies,
it has been shown that the multidrug resistant osteosar-
coma cells exhibited a remarkable increase in well-organ-
ized actin stress fibres; furthermore, dibydrocytoebalasin
B, a specific inhibitor of actin polymerization, that dra-
matically disrupted this network of stress fibres, increased
the intracellular accumulation of doxorubicin (DOX) and
modified the resistance against DOX [27].
To our knowledge, the expression of s100p on B cells or
BCL has never been reported in the English literature
while it has been described on T cells expressing CD8 or
CD4. One of the earliest reports documented that s100p+
T lymphocytes were CD8+ small lymphocytes with poorly
developed cellular organelles and unclear function [28].
The expression of s100p on T cell lymphoproliferative dis-
orders has been associated with poor clinical outcome for
all the reported cases. Initially, a report identifying a
tumor with intermediate features between TCL and malig-
Table 3: Clinico-pathological characteristics of the studies cases
N° Sex/age stage Site of biopsy Histologic variant CD10 Bcl-6 Mum-1 Bcl-2 MIB-1 subtype
1 F/60 I CNS, parietal CBp - ++ +++ ++++ 25% Type 3
2 M/40 I CNS, extradural CBp, anaplastic cells - - +++ - 50% ABC
3 F/55 I CNS, frontal CBp - ++ ++++ ++++ 25% Type 3
4 F/45 III Nodal, axillary T/HRTCL - - +++ ++++ 90% ABC
5 M/70 III Nodal, cervical CBp - ++ +++ +++ 25% Type 3
6 F/66 III Nodal, inguinal CBp - - +++ ++++ 75% ABC
7 M/23 II Nodal, cervical CB +++ ++ - - 50% GC
8 F/74 I Nodal, abdominal CBp +++ ++ - - 25% GC
9 M/50 I Nodal, cervical CB - ++ - - 25% GC
10 F/52 III Nodal, inguinal CBp, anaplastic cells - +++ +++ +++ 90% Type 3
11 M/43 III Nodal, inguinal CBp - - - ++ 90% Type 3
12 M/55 IV Nodal, abdominal CBp, anaplastic cells - - + ++++ 75% ABC
13* M/34 IV Nodal, abdominal CBp, anaplastic, clear cells - ++ +++ ++++ 90% Type 3
14 M/48 III Nodal, cervical CBp - +++ ++ ++++ 75% Type 3
15 M/49 I Nodal, cervical CB ++ - - - 50% GC
16 F/11 II Nodal, abdominal CBp, clear cells - - + ++++ 50% ABC
17 F/9 I Nodal, cervical CBp, anaplastic, clear cells +++ ++ - - 10% GC
18 M/37 I Nodal, cervical CB p, anaplastic cells +++ +++ - - 50% GC
19 M/56 III Nodal, cervical CBp, clear cells - - +++ ++ 90% ABC
20 F/63 III Nodal, abdominal CBp, anaplastic cells +++ +++ - - 50% GC
21 M/31 I Extranodal, Appendicular CBp - - ++++ - 90% ABC
22 M/15 I Extranodal, gastric CBp ++ ++ - - 90% GC
23 F/49 I Extranodal, gastric CB - - - - 25% Type 3
24 M/70 I Extranodal, gastric CBp - +++ +++ ++++ 90% Type 3
25 M/35 I Extranodal, omentum CBp +++ - - - 10% GC
26 M/52 I Extranodal, spleen Histiocyte-like, anaplastic cells - ++ - - 25% GC
27* F/43 I Extranodal, retro-orbital CBp - - - +++ 90% Type 3
28 F/45 I Extranodal, scapular CBp, spindle, clear cells - ++ +++ ++++ 75% Type 3
29 F/46 I Extranodal, iliac bone CBp, clear cells +++ ++ - - 10% GC
CB: centroblastic
CB p: centroblastic polymporph
T/HRTCL: Tcell/histiocyte rich B cell lymphoma
CNS: central nervous system
* dead from the diseaseDiagnostic Pathology 2007, 2:9 http://www.diagnosticpathology.org/content/2/1/9
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SMA staining showing positivity of the lymphocytes and inter- nal control of the blood vessels, DAB, Hx, × 10 Figure 4
SMA staining showing positivity of the lymphocytes and inter-
nal control of the blood vessels, DAB, Hx, × 10.
Centroblastic polymorph variant on H&E staining, × 40 Figure 1
Centroblastic polymorph variant on H&E staining, × 40.
CD79a membranous staining of the lymphocytes, DAB, Hx,  × 40 Figure 2
CD79a membranous staining of the lymphocytes, DAB, Hx, 
× 40.
Strong nuclear, nucleolar Mum-1 staining of 50% of the neo- plastic lymphocytes, DAB, Hx, × 40 Figure 3
Strong nuclear, nucleolar Mum-1 staining of 50% of the neo-
plastic lymphocytes, DAB, Hx, × 40.Diagnostic Pathology 2007, 2:9 http://www.diagnosticpathology.org/content/2/1/9
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Bcl-2 membranous staining of the neoplastic lymphocytes,  DAB, Hx, × 40 Figure 8
Bcl-2 membranous staining of the neoplastic lymphocytes, 
DAB, Hx, × 40.
Nuclear staining of s100p of all neoplastic lymphocytes, DAB,  Hx, × 10 Figure 6
Nuclear staining of s100p of all neoplastic lymphocytes, DAB, 
Hx, × 10.
Higher power magnification of figure 4 showing moderate  nuclear and rare cytoplasmic SMA staining of the neoplastic  lymphocytes, DAB, Hx, × 40 Figure 5
Higher power magnification of figure 4 showing moderate 
nuclear and rare cytoplasmic SMA staining of the neoplastic 
lymphocytes, DAB, Hx, × 40.
Higher power magnification of figure 6 showing moderate to  strong nuclear for s100p, DAB, Hx, × 40 Figure 7
Higher power magnification of figure 6 showing moderate to 
strong nuclear for s100p, DAB, Hx, × 40.Diagnostic Pathology 2007, 2:9 http://www.diagnosticpathology.org/content/2/1/9
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nant histiocytosis has been described; patient had fever,
pancytopenia with relative increase of CD8 lymphocytes,
severe bone marrow (BM) hypoplasia, generalized lym-
phadenopathy and splenomegaly [29]. A rapidly fatal dis-
ease of a 12 years old boy presenting with sinusoidal
pattern of paraoaortic nodal involvement, thrombocyto-
penia, splenomegaly and BM involvement was s100p+
CD4+ CD8- TCL [30]. Three out of four cases of s100+
alpha/beta chain TCL presenting with hepatosplenomeg-
aly and CNS involvement had a fatal outcome despite
treatment [31]. A second case of s100p+ hepatosplenic
alpha/beta TCL and pancytopenia has been described
[32]. A 12 years old boy died shortly after diagnosis from
an aggressive s100p+ CD56+ non-nasal T cell lymphopro-
liferative disorder presenting with splenic and marrow
involvement [33]. In non haematological malignancies,
s100p expression was significantly associated with
decreased survival and was an independent predictor of
poor prognosis in non-small cell lung cancer [34].
In conclusion, this is the first observation to report the
expression of both SMA and s100p on non GC DLBCL.
These markers appear to be adverse prognostic factors.
Future studies evaluating the significance of these markers
in conjunction with other biomarkers will be valuable to
assess the different subgroups in clinical context. Lastly,
the observed SMA and s100p reactivity in DLBCL may
lead to a misdiagnosis of non-haematopoietic malignan-
cies if lymphoid markers are not included in the IHC
panel.
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Table 4: correlation between DLBCL subgroups and SMA, s100p, bcl-2 and MIB-1
Subtype s100p (p = 0.025) SMA (p < 0.01) bcl-2 (p < 0.001) MIB-1 (p < 0.01) Total
- + ++ +++ ++++ - ++ +++ ++++ - ++ +++ ++++ <50% >50%
GC 9 2 0 0 0 10 1 0 0 11 0 0 0 10 1 11
A B C 2 0 1 1 3 02 1 4 21 0 4 2 5 7
t y p e  3 3 0 4 2 2 25 2 2 11 3 6 4 7 1 1
Total 14 2 5 3 5 12 8 3 6 14 2 3 10 16 13 29
High proliferation fraction as noted by the staining of up to  75% of the neoplastic lymphocytes, MIB-1, DAB, Hx, × 10 Figure 9
High proliferation fraction as noted by the staining of up to 
75% of the neoplastic lymphocytes, MIB-1, DAB, Hx, × 10.
Higher power magnification of figure 9 showing strong  nuclear staining of the neoplastic lymphocytes, MIB-1, DAB,  Hx, × 40 Figure 10
Higher power magnification of figure 9 showing strong 
nuclear staining of the neoplastic lymphocytes, MIB-1, DAB, 
Hx, × 40.Diagnostic Pathology 2007, 2:9 http://www.diagnosticpathology.org/content/2/1/9
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